Recently, the research results of a multicenter, randomized and controlled clinical trial independently completed by Chinese experts were published in The New England Journal of Medicine (with an impact factor of 91.245) with the article title of “Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension”.

The findings of this study demonstrated that in 60-80 years old Chinese patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg, which updated the previous standard of <140 mmHg widely-recognized by the experts. Meantime,The New England Journal of Medicinealso published an Editorial entitled “Moving the Goalposts for Blood Pressure -Time to Act”, proposing that the Trial confirmed that "the decline of systolic blood pressure lower than the currently-accepted target value can effectively provide clinical benefits and relatively high safety". As one of the co-authors and co-affiliations of the Trial, Professor Tian Gang and Department of Cardiovascular Medicine of the First Affiliated Hospital of Xi 'an Jiaotong University (XJTU) completed this 4-year high-quality clinical trial with rigorous scientific attitude.